Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985999 | 0.87 | L3MBTL1 (0.42) | HTR2CL3MBTL1LMNAALDH1A1NR1H4 | |
| SCHEMBL14778992 | 0.76 | HTR2C (0.51) | HTR2CL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL2983787 | 0.72 | HTR2C (0.46) | HTR2CL3MBTL1LMNAALDH1A1NR1H4 | |
| SCHEMBL6819973 | 0.68 | SMN1; SMN2 (0.48) | HTR2CL3MBTL1LMNAALDH1A1MEN1 | |
| SCHEMBL16356837 | 0.68 | POLB (0.52) | HTR2CL3MBTL1LMNAKDM4E | |
| SCHEMBL7658562 | 0.67 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10053573 | 0.67 | HTR2C (0.64) | HTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL5517077 | 0.67 | HTR2C (0.64) | HTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL5517082 | 0.67 | HTR2C (0.64) | HTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL8562576 | 0.67 | KMT2A (0.48) | HTR2CL3MBTL1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950198-B1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | TORAY FINECHEMICALS CO LTD (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-7772406-B2 | Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090093643-A1 | Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1950198-A1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093643-A1 | Process for Production of Benzyloxypyrrolidine Derivative, and Process for Production of Hydrochloride Salt Powder of Optically Active Benzyloxypyrrolidine Derivative | HPD, PAH, DHPS | HTR2C 1924/4885L3MBTL1 3977/4885LMNA 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.